CYP3A4 and breast cancer: In another study focusing on locally advanced breast cancer patients, those with low circulating CYP3A4 mRNA levels showed higher response rates to docetaxel compared to patients with elevated CYP3A4 mRNA levels (p < 0.01) [77].